Stifel Financial
ZYNE

Stifel Financial’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Stifel Financial’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,000
Closed -$130K – 2803
2018
Q1 		$130K Buy
15,000
+2,000
+15% +$21.6K ﹤0.01% 2541
2017
Q4 		$163K Buy
13,000
+3,000
+30% +$34.4K ﹤0.01% 2484
2017
Q3 		$84K Buy
+10,000
New +$106K ﹤0.01% 2485

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stifel Financial's ZYNE Position: Q2 2018 in Review

Stifel Financial sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2018, closing a stake of 15,000 shares — an estimated $130K sold.

Stifel Financial first reported a position in ZYNE in Q3 2017 and held it in 3 quarters. The position peaked at $163K in Q4 2017. 59 funds tracked by Wall St. Rank hold ZYNE as of Q2 2018.

  • Stifel Financial reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2018 after selling out during the quarter.
  • Stifel Financial sold 15,000 Zynerba Pharmaceuticals, Inc shares in Q2 2018, an estimated $130K.
  • Stifel Financial first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2017 and held it in 3 quarters.
  • Stifel Financial's Zynerba Pharmaceuticals, Inc position peaked at $163K in Q4 2017.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2018.

Based on Stifel Financial's 13F filing for Q2 2018, filed 14 Aug 2018.